NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

British Journal of Cancer

Volumn 82, Issue 3, 2000, Pages 651-656

  Saunders, M P ^a   Patterson, A V ^a   Chinje, E C ^a   Harris, A L ^b   Stratford, I J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Bioreductive drugs; Cytochrome P450 reductase; Hypoxia; Tirapazamine

Indexed keywords

3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; COMPLEMENTARY DNA; DRUG METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; TIRAPAZAMINE; TPZ; UNCLASSIFIED DRUG;

ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CANCER; OXIDATION; OXYGENATION; PRIORITY JOURNAL;

EID: 0033967539     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0977     Document Type: Article

References (25)

1. Adams GE and Stratford IJ (1994) Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys 29: 231-238
2. Brown JM (1993) SR4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163-1170
3. Brown JM and Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Res 50: 7745-7749
4. Chaplin DJ, Olive PL and Durrand RE (1987) Intermittent blood flow in a murine tumour: radiobiological effects. Cancer Res 47: 597-601
5. Dorie MJ and Brown JM (1993) Tumour-specific schedule dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633-4636
6. Elwell JH, Siim BG, Evans JW and Brown JM (1997) Adaption of human tumour cells to tirapazamine under aerobic conditions. Biochem Pharmacol 54: 249-257
7. Evans JW, Yudoh K, Delahoussaye YM and Brown JM (1998) Tirapazamine is metabolised to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58: 2098-2101
8. Forkert PG, Lord JA and Parkinson A (1996) Alterations in expression of CYP1A1 and NADPH-cytochrome P450 reductase during lung tumor development in SWR/J mice. Carcinogenesis 17: 127-134
9. Forrester LM, Hayes JD, Millis R, Barnes D, Harris AL, Schlager JJ, Powis G and Wolf CR (1990) Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 11: 2163-2170
10. Jain RK (1988) Determinants of tumour blood flow. Cancer Res 48: 2641-2658
11. Laderoute K, Wardman P and Rauth AM (1988) Molecular mechanisms for the hypoxic-dependent activation of 3-amino-1,2,4-benzotriazene-1,4-dioxide (SR4233). Biochem Pharmacol 37: 1487-1495
12. Lee D, Trotti A, Spencer S, Rostock R, Fisher C, von Roemeling R, Harvey E and Groves E (1998) A phase II trial of radiotherapy with concurrent tirapazamine, a hypoxic cytotoxin, for advanced head and neck carcinomas. Int J of Radiat Oncol Biol Phys (in press)
13. Lloyd RV, Duling DR, Rumyantseva GV, Mason RP and Bridson PK (1991) Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 40: 440-445
14. Overgaard J (1992) Importance of tumour hypoxia in radiotherapy: a meta-analysis of controlled clinical trials. Radiother Oncol 24: Abs-S64
15. Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL, Stratford IJ and Carmichael J (1994) The role of DT-diaphorase in determining the sensitivity of human tumour cell to tirapazamine (SR 4233). Int J Radiat Oncol Biol Phys 29: 369
16. Patterson AV, Barham HM, Chinje EC, Adams, GE, Harris AL and Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72: 1144-1150
17. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL and Stratford IJ (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR4233) and RSU1069. Br J Cancer 76: 1338-1347
18. Patterson AV, Saunders MP, Chinje EC, Patterson LH and Stratford IJ (1998) Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Design 13: 541-573
19. Plumb JA and Workman P (1994) Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56: 134
20. Riley JR, Hemingway SA, Graham MA, Workman P (1993) Initial characterisation of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotrizene-1,4-di-N-oxide (Tirapazamine, SR 4233. WIN59075). Biochem Pharmacol 45: 1065
21. Robertson N, Haigh A, Adams GE and Stratford IJ (1994) Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 30A: 1013-1019
22. Rodriguez GI, Valdivieso M, Von Hoff DD, Kraut M, Burris HA, Eckardt JR, Lockwood G, Kennedy H and von Roemeling R (1996) A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC) (Meeting abstract). Proc Anna Meet Am Soc Clin Oncol 15: 382
23. Saunders MP, Patterson AV, Jaffar M, Harris AL and Stratford IJ (1996) Structural requirements for EO9 toxicity and dependence on P450 reductase for activation. Br J Cancer supp 73: XXVI, Abs-P6
24. Vaupel P (1993) Oxygenation of solid tumours. In: Drug Resistance in Oncology, Teicher BA (ed). pp. 59-85. Marcel Dekker: New York
25. Workman P and Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12: 73-82